Five takeaways from its financial results:
1. Revenue in the first quarter was $402.1 million, up 16 percent from the same period last year.
2. Net loss was $31.2 million, or $0.18 per share.
3. Screening revenue, which includes Cologuard tests, increased 10 percent at $240.3 million.
4. Precision oncology revenue was $129.4 million, and COVID-19 testing revenue was $32.3 million.
5. The company expects revenue of $1.7 billion this year, with $1.1 billion of that coming from screening products this year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
